[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576188":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":28,"centralContacts":45,"locations":51,"responsibleParty":72,"collaborators":74,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":28,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":28,"enrollmentInfo":88,"targetDuration":28,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":101,"whyStopped":28,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"National University Hospital, Singapore","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Pyrvinium","EXPERIMENTAL","Pyrvinium will be administered to participants.",[13,14,15,16],"Drug: Pyrvinium","Procedure: Blood biomarkers analyses","Procedure: Oesophagogastroduodenoscopy (OGD) and biopsy","Other: Gastric juice, saliva and stool collection and analyses",{"label":18,"type":19,"description":20,"interventionNames":21},"Placebo","PLACEBO_COMPARATOR","Placebo will be administered to participants.",[22,14,15,16],"Drug: Placebo",[24,29,32,37,41],{"type":25,"name":18,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Participants will receive placebo by mouth once each day for a total of 14 days.",[18],null,{"type":25,"name":9,"description":30,"armGroupLabels":31,"otherNames":28},"Participants will receive pyrvinium (2 mg\u002Fkg\u002Fday) by mouth once each day for a total of 14 days.",[9],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":28},"PROCEDURE","Blood biomarkers analyses","Up to 20ml of blood will be drawn from each participant at each study visit, with a total of 4 study visits for molecular analyses.",[18,9],{"type":33,"name":38,"description":39,"armGroupLabels":40,"otherNames":28},"Oesophagogastroduodenoscopy (OGD) and biopsy","Study participant will undergo OGD with collection of gastric mucosal biopsies at the baseline visit to ascertain IM status and for molecular analyses. Study participant will undergo follow-up gastroscopy with collection of gastric mucosal biopsies at day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment to assess if endpoint is reached and for molecular analyses. Gastric juice samples will be collected during each OGD.",[18,9],{"type":6,"name":42,"description":43,"armGroupLabels":44,"otherNames":28},"Gastric juice, saliva and stool collection and analyses","Gastric juice will be taken, and gastric pH will be measured at each research endoscopy. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, 6 weeks post-treatment, and 1 year post-treatment.",[18,9],[46],{"name":47,"role":48,"phone":49,"phoneExt":28,"email":50},"Jonathan Wei Jie Lee, MBBS, MRCP, MCI","CONTACT","+6567723951","jonathanlee@nus.edu.sg",[52],{"facility":53,"status":28,"city":54,"state":28,"zip":55,"country":54,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"National University Hospital","Singapore","122107","SG",{"type":58,"coordinates":59},"Point",[60,61],103.85007,1.28967,{"lat":61,"lon":60},[64,65,67,70],{"name":47,"role":48,"phone":49,"phoneExt":28,"email":50},{"name":47,"role":66,"phone":28,"phoneExt":28,"email":28},"PRINCIPAL_INVESTIGATOR",{"name":68,"role":69,"phone":28,"phoneExt":28,"email":28},"Jimmy Bok Yan So, MBChB, FRCSEd, FRCSG, MPH","SUB_INVESTIGATOR",{"name":71,"role":69,"phone":28,"phoneExt":28,"email":28},"Wei Peng Yong, MBChB, MRCP",{"type":73,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[75,77],{"name":76,"class":6},"National University of Singapore",{"name":78,"class":6},"Vanderbilt University Medical Center","100576188","phase-2-use-of-pyrvinium-to-reverse-stomach-precancerous-conditions-100576188",false,"NCT06782048","Use of Pyrvinium to Reverse Stomach Precancerous Conditions","Pyrvinium for Reversal of Precancerous Metaplasia and Dysplasia in the Stomach","Inclusion Criteria:\n\n* The subject is at least 21 years of age.\n* The subject has histologically proven extensive\u002Fmarked intestinal metaplasia and\u002For dysplasia.\n* The subject is willing and able to provide signed and dated patient informed consent form indicating that he\u002Fshe has been informed of all pertinent aspects of the study.\n\nExclusion Criteria:\n\n* The subject has an active gastric cancer diagnosis.\n* The subject is pregnant.\n* The subject has a high-risk of bleeding complications due to anticoagulants or underlying medical condition such as bleeding disorders in whom biopsies are contraindicated.\n* The subject has impaired renal function.\n* The subject has impaired hepatic function.\n* The subject has fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency.\n* The subject has chronic bowel disease.\n* The subject has any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and in the judgement of the investigator would make the subject unsuitable for entry into the study.\n* The subject is unwilling or unable to provide signed informed consent.","ALL","21 Years",{"count":89,"type":90},50,"ESTIMATED","INTERVENTIONAL",[93],"PHASE2","This study is carried out to find out if a drug called pyrvinium is able to convert pre-cancerous tissue in the stomach back to healthy tissue, to lower the chances of stomach cancer. Pyrvinium is a drug that has been used for a long time to treat pinworms in children and its anti-cancer properties are currently under investigation. Tests in animals have shown that pyrvinium made unhealthy tissue healthier and stopped some cells from growing in a bad way. Based on preclinical studies, the investigators hypothesise that the proportion of samples with pre-cancerous tissue in the stomach would decrease by 50% after exposure to pyrvinium at the 6-week timepoint, with anticipated durability of the response at the one-year follow-up.",[96],"STOMACH NEOPLASM",[98,99,100,9],"Gastric Cancer","Stomach Neoplasm","Intestinal Metaplasia","NOT_YET_RECRUITING","2025-01-13",{"date":104,"type":105},"2025-01-17","ACTUAL",{"date":107,"type":90},"2025-08",{"date":109,"type":90},"2029-12",{"name":5,"class":6},1]